This interview with a Germany-based key opinion leader (KOL) provides insights into current clinical practice in alpha-1 antitrypsin deficiency (AATD), including population definitions, the role of augmentation therapy and the safety and efficacy of mid- to late-stage pipeline assets. Key assets covered include Prolastin-C, Zemaira (Respreeza, EU), Glassia, fazirsiran, efdoralprin alfa and alvelestat.

This interview was conducted on August 18, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.